第一三共、Dato-DXdのTNBC一次治療でFDA優先審査──TROPION-Breast02に基づく生物学的製剤一部変更承認申請が受理 | STELLANEWS.LIFE STELLANEWS.LIFE（ステラニュース・ライフ）は、科学や技術、医薬品分野における最新の研究成果や発見 | STELLANEWS.LIFE（ステラニュース・ライフ）は、科学や技術、医薬品分野における最新の研究成果や発見

第一三共、Dato-DXdのTNBC一次治療でFDA優先審査──TROPION-Breast02に基づく生物学的製剤一部変更承認申請が受理
FDA grants Priority Review for datopotamab deruxtecan in first-line TNBC based on TROPION-Breast02

stellanews.life/technology/8...

#TNBC #BreastCancer #DatoDXd #TROP2 #FDA #PriorityReview

Paolo Tarantino on Investigating Dato-DXd in HER2- Breast Cancer Brain Metastases - VJ Oncology - OncoDaily Paolo Tarantino on Investigating Dato-DXd in HER2- Breast Cancer Brain Metastases - VJ Oncology / Breast Cancer, cancer, Dana-Farber Cancer Institute,

VJ Oncology - Paolo Tarantino on Investigating Dato-DXd in HER2- Breast Cancer Brain Metastases

@ptarantinomd.bsky.social

oncodaily.com/voices/dato-...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #DatoDXd #BreastCancer #mBC

Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis Abstract. Oral mucositis/stomatitis (hereafter stomatitis) is a common dose-limiting toxicity seen with various classes of cancer treatment. Symptoms assoc

Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis academic.oup.com/oncolo/artic...
#SuppOnc #DatoDXd @hoperugo.bsky.social

Datopotamab deruxtecan now #FDA approved off #TROPIONBreast01: #DatoDXd Vs Chemo post 1-2L HR+ mBC

- ⏰ to 1st Rx: 8.2 vs 5mos (favoring Dato)
- ⬆️ PFS 6.9mos vs 4.5 mos
- Better AE + QoL favoring DatoDXd
- AEs: Fatigue, infusion reactions, stomatitis

#bcsm #OncSky #MedSky